Purpose: To report an unusual case of delayed endophthalmitis in a young patient treated for serpiginous choroidopathy. Methods: A single case was reviewed. Results: An 18-year-old patient developed endophthalmitis 3 years after intravitreal (IVT) implantation of fluocinolone acetonide (0.59 mg). The delayed infection was likely secondary to a persistent patent sclerotomy resulting from poor wound healing of the large incision created during implantation. Conclusions: Smaller sclerotomies and additional permanent sutures may help ensure secure closure of implantation wounds and reduce the risk of delayed reopening and subsequent endophthalmitis. Patients should be counseled on the risk of delayed endophthalmitis after implantation of IVT fluocinolone acetonide and advised to seek immediate ophthalmic care if signs or symptoms of infection develop.
KismaNRobsonAGHolderGEWestcottMPavesioC.Long term outcome of birdshot chorioretinopathy treated by fluocinolone acetonide intravitreal implant (Retisert®): a case series report. Invest Ophthalmol Vis Sci. 2011;52(14):2737-2737.
2.
MohammadDASweetBVElnerSG.Retisert: is the new advance in treatment of uveitis a good one?Ann Pharmacother. 2007;41(3):449-454.
3.
BrummMVNguyenQD.Fluocinolone acetonide intravitreal sustained release device–a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64.
4.
GeorgalasIKoutsandreaCPapaconstantinouDMpouritisDPetrouP.Scleral melt following Retisert intravitreal fluocinolone implant. Drug Des Devel Ther. 2014;8:2373-2375.
5.
AllenRCSuhlerEBFlaxelCJChenZChoiD.Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):177-182.
6.
TabanMLowderCYVenturaAA, et al. Scleral thickness following fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm. 2010;18(4):305-313.
7.
PanjaphongseRStewartJM.Risk factors for wound leakage after Ozurdex injection. Ocul Immunol Inflamm. 2015;23(5):410-411.
RobertMCHamelPBlondeauPLeskMR.Persistent leak after glaucoma aqueous shunt implantation. J Glaucoma. 2013;22(8):647-651.
10.
WooSJParkKHHwangJMKimJHYuYSChungH.Risk factors associated with sclerotomy leakage and postoperative hypotony after 23-gauge transconjunctival sutureless vitrectomy. Retina. 2009;29(4):456-463.
11.
RofaghaSPrechanondTStewartJM.Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert) [published correction appears in Ocul Immunol Inflamm. 2013 Jun;21(3):255]. Ocul Immunol Inflamm. 2013;21(1):77-78.
12.
VanderBeekBLBonaffiniSGMaL.The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311-2315.e1.
13.
Cruz-IñigoYJKleinKReddyRK.Case report of abiotrophia defectiva endophthalmitis after repeated injections of dexamethasone intravitreal implant (Ozurdex). Retin Cases Brief Rep. 2022;16(2):170-173.
14.
PasrichaMVCallawayNFMahajanVB.Intravitreal fluocinolone acetonide (Retisert) implantation using a keratome blade. J Vitreoretin Dis. 2020;5(1):66-67.
15.
BergerBBMendozaW.Sclerotomy closure for Retisert implant. Retina. 2013;33(2):436-438.
16.
CainWJrSinskeyRM.Detection of anterior chamber leakage with Seidel’s test. Arch Ophthalmol. 1981;99(11):2013.
17.
ChanHHLKongYXG.Glaucoma surgery and induced astigmatism: a systematic review. Eye Vis (Lond). 2017;4:27. doi:10.1186/s40662-017-0090-x
WuZHChanRPLukFO, et al. Review of clinical features, microbiological spectrum, and treatment outcomes of endogenous endophthalmitis over an 8-year period. J Ophthalmol. 2012;2012:265078.
21.
WangXZhangPSuoJLiQZhangY.The diagnosis and treatment progress of infectious endophthalmitis. Eye (Lond). 2025;39:492-504.
